The effect of GHRH antagonists on human glioblastomas and their mechanism of action

Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125, USA.
International Journal of Cancer (Impact Factor: 5.09). 11/2010; 127(10):2313-22. DOI: 10.1002/ijc.25259
Source: PubMed


The effects of new growth hormone-releasing hormone (GHRH) antagonists JMR-132 and MIA-602 and their mechanism of action were investigated on 2 human glioblastoma cell lines, DBTRG-05 and U-87MG, in vitro and in vivo. GHRH receptors and their main splice variant, SV1 were found on both cell lines. After treatment with JMR-132 or MIA-602, the cell viability decreased significantly. A major decrease in the levels of phospho-Akt, phospho-GSK3β and phosho-ERK 1/2 was detected at 5 and 10 min following treatment with the GHRH antagonists, whereas elevated levels of phospho-p38 were observed at 24 hr. The expression of caspase-3 and poly(ADP-ribose) (PARP), as the downstream executioners of apoptosis were found to be significantly elevated after treatment. Following treatment of the glioblastoma cells with GHRH antagonists, nuclear translocation of apoptosis inducing factor (AIF) and Endonuclease G (Endo G) and the mitochondrial release of cytochrome c (cyt c) were detected, indicating that the cells were undergoing apoptosis. In cells treated with GHRH antagonists, the collapse of the mitochondrial membrane potential was shown with fluorescence microscopy and JC-1 membrane potential sensitive dye. There were no significant differences between results obtained in DBTRG-05 or U-87MG cell lines. After treatment with MIA-602 and JMR-132, the reduction rate in the growth of DBTRG-05 glioblastoma, xenografted into nude mice, was significant and tumor doubling time was also significantly extended when compared with controls. Our study demonstrates that GHRH antagonists induce apoptosis through key proapoptotic pathways and shows the efficacy of MIA-602 for experimental treatment of glioblastoma.

  • Source

    Preview · Article ·
  • [Show abstract] [Hide abstract]
    ABSTRACT: Induction of caspase-dependent apoptosis (type I cell death) is a major mechanism by which most chemotherapeutic drugs and radiation kill tumor cells. However, conventional cancer therapies fail to mediate their effects in a target-specific fashion. The extremely unfavorable prognosis for patients suffering from glioblastomas (GBMs) is strongly correlated to the intrinsic apoptosis resistance of GBM cells which especially occurs in diffusely migrating tumor cells. The ultimate goal for molecular, apoptosis-based therapies is to target specific components of the two major apoptotic pathways, i.e. the extrinsic and the intrinsic pathway to trigger tumor-selective apoptosis, while at the same time limiting toxicity in normal tissues. Induction of autophagic cell death (type II cell death) by pro-autophagic drugs is an alternative and emerging concept to trigger glioma cell death and to exploit caspase-independent programmed cell death pathways for the development of novel glioma therapies. This review provides an up to date and comprehensive report on the relevant pre-clinical and clinical drugs interfering with the major apoptosis and autophagy pathways, their therapeutic potential in glioma and adresses potential future perspectives in this exciting field of research.
    No preview · Article · Sep 2010 · Anti-cancer agents in medicinal chemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Growth Hormone-Releasing Hormone (GHRH) is secreted by the hypothalamus and regulates the release of growth hormone from the anterior pituitary gland. In addition to its endocrine role, this peptide has been shown to act as a growth factor in diverse malignancies. Recent studies indicate that GHRH is also a regulator of several important physiological processes. These processes which include the regulation of the metabolism of the reactive oxygen and nitrogen species are similarly enhanced by GHRH agonists. In contrast, GHRH antagonists can counteract the growth factor effects of GHRH. GHRH and its agonists have been shown to contribute to the recovery of heart tissue after myocardial infarction and can promote the survival and proliferation of pancreatic islets after transplantation into diabetic animals.
    Preview · Article · Oct 2010 · Cell cycle (Georgetown, Tex.)
Show more